TNSN04001A1 - Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. - Google Patents
Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.Info
- Publication number
- TNSN04001A1 TNSN04001A1 TNP2004000001A TNSN04001A TNSN04001A1 TN SN04001 A1 TNSN04001 A1 TN SN04001A1 TN P2004000001 A TNP2004000001 A TN P2004000001A TN SN04001 A TNSN04001 A TN SN04001A TN SN04001 A1 TNSN04001 A1 TN SN04001A1
- Authority
- TN
- Tunisia
- Prior art keywords
- hmg
- coa
- association
- receptor antagonist
- aldosterone receptor
- Prior art date
Links
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 title abstract 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30633601P | 2001-07-19 | 2001-07-19 | |
| PCT/US2002/022896 WO2003007993A1 (en) | 2001-07-19 | 2002-07-18 | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN04001A1 true TNSN04001A1 (fr) | 2006-06-01 |
Family
ID=23184836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2004000001A TNSN04001A1 (fr) | 2001-07-19 | 2004-01-06 | Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20030149010A1 (enExample) |
| EP (1) | EP1406660B1 (enExample) |
| JP (1) | JP2004537553A (enExample) |
| KR (1) | KR20040023660A (enExample) |
| CN (1) | CN1537019A (enExample) |
| AP (1) | AP2004002951A0 (enExample) |
| AT (1) | ATE363917T1 (enExample) |
| BR (1) | BR0211274A (enExample) |
| CA (1) | CA2452678A1 (enExample) |
| CO (1) | CO5550464A2 (enExample) |
| DE (1) | DE60220522T2 (enExample) |
| EA (1) | EA200400029A1 (enExample) |
| EC (1) | ECSP044950A (enExample) |
| ES (1) | ES2286270T3 (enExample) |
| GE (1) | GEP20063811B (enExample) |
| IL (1) | IL159588A0 (enExample) |
| IS (1) | IS7093A (enExample) |
| MA (1) | MA27050A1 (enExample) |
| MX (1) | MXPA04000586A (enExample) |
| NO (1) | NO20040211L (enExample) |
| OA (1) | OA12983A (enExample) |
| PL (1) | PL367417A1 (enExample) |
| TN (1) | TNSN04001A1 (enExample) |
| UA (1) | UA76475C2 (enExample) |
| WO (1) | WO2003007993A1 (enExample) |
| ZA (1) | ZA200400288B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
| PT1773768T (pt) | 2004-07-30 | 2018-11-30 | Exelixis Inc | Derivados de pirrol como agentes farmacêuticos |
| WO2007005941A2 (en) | 2005-07-05 | 2007-01-11 | President And Fellows Of Harvard College | Liver targeted conjugates |
| CN1310941C (zh) * | 2005-07-13 | 2007-04-18 | 南京大学 | 依普利酮的合成方法 |
| BRPI0618379A2 (pt) * | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| GB0600967D0 (en) * | 2006-01-18 | 2006-03-01 | Imp Innovations Ltd | Methods |
| WO2007106862A2 (en) * | 2006-03-14 | 2007-09-20 | Kinemed, Inc. | The use of statins to stimulate neurogenesis |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| FR2917975B1 (fr) * | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| EP2367554A4 (en) * | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| MX337603B (es) * | 2009-11-30 | 2016-03-10 | Adare Pharmaceuticals Inc | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| RS53227B (sr) | 2011-03-01 | 2014-08-29 | Pharnext | Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata |
| DE102011015142A1 (de) * | 2011-03-17 | 2012-09-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| EA038594B1 (ru) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| KR20160002773A (ko) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
| AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
| US20150199491A1 (en) * | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| EP4424363B1 (en) | 2019-02-12 | 2026-04-29 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| KR20010006443A (ko) * | 1997-04-18 | 2001-01-26 | 쥐.디. 씨얼리 앤드 컴퍼니 | 심장혈관 질환 예방에의 시클로 옥시게나제-2 억제제 사용방법 |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| US6638937B2 (en) * | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| WO2000062775A1 (en) * | 1999-04-19 | 2000-10-26 | The Regents Of The University Of Michigan | Compositions and methods for increasing the bioavailability of lactone ring containing drugs |
-
2002
- 2002-07-18 OA OA1200400005A patent/OA12983A/en unknown
- 2002-07-18 UA UA2004010388A patent/UA76475C2/uk unknown
- 2002-07-18 CN CNA028145577A patent/CN1537019A/zh active Pending
- 2002-07-18 CA CA002452678A patent/CA2452678A1/en not_active Abandoned
- 2002-07-18 AT AT02756521T patent/ATE363917T1/de not_active IP Right Cessation
- 2002-07-18 US US10/198,475 patent/US20030149010A1/en not_active Abandoned
- 2002-07-18 DE DE60220522T patent/DE60220522T2/de not_active Expired - Fee Related
- 2002-07-18 MX MXPA04000586A patent/MXPA04000586A/es active IP Right Grant
- 2002-07-18 PL PL02367417A patent/PL367417A1/xx not_active Application Discontinuation
- 2002-07-18 GE GE5410A patent/GEP20063811B/en unknown
- 2002-07-18 ES ES02756521T patent/ES2286270T3/es not_active Expired - Lifetime
- 2002-07-18 EA EA200400029A patent/EA200400029A1/ru unknown
- 2002-07-18 WO PCT/US2002/022896 patent/WO2003007993A1/en not_active Ceased
- 2002-07-18 BR BR0211274-4A patent/BR0211274A/pt not_active IP Right Cessation
- 2002-07-18 JP JP2003513598A patent/JP2004537553A/ja active Pending
- 2002-07-18 AP APAP/P/2004/002951A patent/AP2004002951A0/en unknown
- 2002-07-18 IL IL15958802A patent/IL159588A0/xx unknown
- 2002-07-18 EP EP02756521A patent/EP1406660B1/en not_active Expired - Lifetime
- 2002-07-18 KR KR10-2004-7000846A patent/KR20040023660A/ko not_active Ceased
-
2003
- 2003-12-23 IS IS7093A patent/IS7093A/is unknown
-
2004
- 2004-01-06 TN TNP2004000001A patent/TNSN04001A1/fr unknown
- 2004-01-14 ZA ZA2004/00288A patent/ZA200400288B/en unknown
- 2004-01-15 MA MA27479A patent/MA27050A1/fr unknown
- 2004-01-16 NO NO20040211A patent/NO20040211L/no not_active Application Discontinuation
- 2004-01-19 CO CO04002848A patent/CO5550464A2/es not_active Application Discontinuation
- 2004-01-19 EC EC2004004950A patent/ECSP044950A/es unknown
-
2005
- 2005-08-18 US US11/206,499 patent/US20060003975A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2286270T3 (es) | 2007-12-01 |
| GEP20063811B (en) | 2006-05-10 |
| NO20040211L (no) | 2004-03-16 |
| CO5550464A2 (es) | 2005-08-31 |
| MA27050A1 (fr) | 2004-12-20 |
| EP1406660B1 (en) | 2007-06-06 |
| KR20040023660A (ko) | 2004-03-18 |
| IS7093A (is) | 2003-12-23 |
| US20030149010A1 (en) | 2003-08-07 |
| EA200400029A1 (ru) | 2004-08-26 |
| PL367417A1 (en) | 2005-02-21 |
| US20060003975A1 (en) | 2006-01-05 |
| ATE363917T1 (de) | 2007-06-15 |
| ECSP044950A (es) | 2004-02-26 |
| ZA200400288B (en) | 2005-06-29 |
| JP2004537553A (ja) | 2004-12-16 |
| DE60220522D1 (de) | 2007-07-19 |
| BR0211274A (pt) | 2004-08-03 |
| UA76475C2 (en) | 2006-08-15 |
| AP2004002951A0 (en) | 2004-03-31 |
| CN1537019A (zh) | 2004-10-13 |
| IL159588A0 (en) | 2004-06-01 |
| DE60220522T2 (de) | 2007-09-27 |
| MXPA04000586A (es) | 2004-04-20 |
| EP1406660A1 (en) | 2004-04-14 |
| WO2003007993A1 (en) | 2003-01-30 |
| CA2452678A1 (en) | 2003-01-30 |
| OA12983A (en) | 2006-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE311200T1 (de) | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten | |
| DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| DZ2618A1 (fr) | Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie. | |
| TNSN00183A1 (fr) | COMPOSITIONS COMPRENANT LE POLYPEPTIDE IL-1ra ET UN INHIBITEUR DE MATURATION ET DE LIBERATION DE IL-1 ET METHODES DE TRAITEMENT LES UTILISANT | |
| ATE516305T1 (de) | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten | |
| TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
| EP2319527A3 (en) | BAFF, inhibitors thereof and their use in the modulation of the B-cell response | |
| NZ595262A (en) | Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease | |
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE59601122D1 (de) | N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten | |
| ATE466009T1 (de) | Ccr5 antagonisten verwendbar für die behandlung von aids | |
| NO20011440D0 (no) | mGluR5-antagonister for behandling av smerte og angst | |
| WO2002066981A3 (en) | Monitoring soluble endothelial protein c receptor levels in anticoagulant therapy | |
| MA27998A1 (fr) | Nouvelle formulation | |
| DE60009888D1 (de) | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen | |
| ATE266420T1 (de) | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| DE69915113D1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression | |
| EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
| MA28561B1 (fr) | Utilisation d'agonistes du recepteur delta active par les proliferateurs de peroxysomes pour le traitement de la sep et d'autres maladies demyelinisantes | |
| MXPA02012257A (es) | Uso de un antagonista de aldosterona para el tratamiento o profilaxis de efectos patogenicos mediados por aldosterona. | |
| SE0300445D0 (sv) | New combination | |
| NO20013459D0 (no) | Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt |